The race for a coronavirus disease 2019 (COVID-19) vaccine is one of the most urgent public health challenges, with multiple vaccine candidates entering phase 3 trials and case counts around the world steadily climbing. MJH Life Sciences™ will host a free webinar with the top minds in infectious disease, virology, and vaccinology to discuss the latest trial information on vaccines.
Phase 3 trials for 2 coronavirus disease 2019 (COVID-19) vaccines have begun, but more than 165 vaccines are being developed around the world. Only 27 vaccines have reached human trials, and Moderna and Pfizer are the only companies with vaccines that have reached the final stage.
Both vaccines use messenger RNA to produce proteins and cause the body’s immune system to attack the virus. In addition, both companies are recruiting 30,000 adults to receive the vaccines.
The race to find a COVID-19 vaccine is the topic of a free webinar from MJH Life Sciences™ (parent company of The American Journal of Managed Care®). The 1-hour webinar, “COVID-19: Race for a Vaccine,” will be held Thursday, July 30, at 6 pm EDT.
The top minds in infectious disease, virology, and vaccinology will provide a breakdown of the top vaccine candidates, outline the latest from the ongoing clinical trials, and discuss how to combat logistical hurdles associated with the rollout of a vaccine in the middle of a global pandemic.
The panel will feature:
With vaccine candidates starting to enter phase 3 trials, governments are pledging huge investments for the first 100 million doses as cases around the world continue climbing. Globally, there have been 655,300 deaths from COVID-19, with the United States leading with 148,298 deaths, according to data from the Johns Hopkins University Coronavirus Resource Center. The United States also leads in the number of confirmed cases, which topped 4.3 million. The total number of confirmed cases around the world has surpassed 16.5 million.
Some countries that had a handle on COVID-19 cases and began reopening are seeing spikes. For instance, Spain opened back up to tourists but has since seen a surge of cases in cities such as Madrid and Barcelona, as well as the island of Mallorca. Vietnam reported the first locally transmitted case in 100 days and 3 residents in Da Nang tested positive, which caused the country to start evacuating 80,000 people, mostly Vietnamese tourists, from the resort city.
The situation remains dire in the United States. After steep increases in cases per capita, Florida is now reporting a 14% decline in cases over the last week; however, there are 20 states reporting increases in cases per capita of 10% or greater in the last week. New York saw an increase of 10%, and Connecticut, New Jersey, and Oklahoma all reported increases in new cases per capita over 100%, according to The Washington Post tracker.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More